Education
About Us
Working with TipRanks
Follow Us
Sonnet BioTherapeutics Holdings (SONN)
NASDAQ:SONN
RESEARCH TOOLSreports
Total Valuation
Sonnet BioTherapeutics Holdings has a market cap or net worth of $3.95M. The enterprise value is $4.33M.
Market Cap$3.95M
Enterprise Value$4.33M
Share Statistics
Sonnet BioTherapeutics Holdings has 3.07M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3.07M
Owned by Insiders7.36%
Owned by Instutions1.29%
Financial Efficiency
Sonnet BioTherapeutics Holdings’s return on equity (ROE) is 15.31 and return on invested capital (ROIC) is 3339.05%.
Return on Equity (ROE)1531.12%
Return on Assets (ROA)-268.39%
Return on Invested Capital (ROIC)3339.05%
Return on Capital Employed (ROCE)2698.18%
Revenue Per Employee$84,953.231
Profits Per Employee-$725,340.692
Employee Count13
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Sonnet BioTherapeutics Holdings is -0.59. Sonnet BioTherapeutics Holdings’s PEG ratio is 0.02.
PE Ratio-0.59
PS Ratio235.35
PB Ratio-9.02
Price to Fair Value-9.02
Price to FCF-0.51
Price to Operating Cash Flow-0.51
PEG Ratio0.02
Income Statement
In the last 12 months, Sonnet BioTherapeutics Holdings had revenue of $1.10M and earned -$9.43M in profits. Earnings per share was -$6.95.
Revenue$1.10M
Gross Profit-$3.48M
Operating Income-$13.42M
Pretax Income-$9.27M
Net Income-$9.43M
EBITDA-13.38M
Earnings Per Share (EPS)-6.95
Cash Flow
In the last 12 months, operating cash flow was -$8.43M and capital expenditures -$12.00K, giving a free cash flow of -$8.44M billion.
Operating Cash Flow-$8.43M
Free Cash Flow-$8.44M
Free Cash Flow per Share-$2.75
Dividends & Yields
Sonnet BioTherapeutics Holdings pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-196.36%
Earnings Yield-169.66%
Stock Price Statistics
Beta1.18
52-Week Price Change-91.09%
50-Day Moving Average1.43
200-Day Moving Average3.85
Relative Strength Index (RSI)44.05
Average Volume (3m)46.08K
Important Dates
Sonnet BioTherapeutics Holdings upcoming earnings date is May 20, 2025, Before Open.
Last Earnings DateFeb 13, 2025
Next Earnings DateMay 20, 2025
Ex-Dividend Date―
Financial Position
Sonnet BioTherapeutics Holdings as a current ratio of 0.66, with Debt / Equity ratio of -0.27
Current Ratio0.66
Quick Ratio0.66
Debt to Market Cap0.00
Net Debt to EBITDA<0.01
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Sonnet BioTherapeutics Holdings has paid $158.40K in taxes.
Income Tax$158.40K
Effective Tax Rate0.00%
Enterprise Valuation
Sonnet BioTherapeutics Holdings EV to EBITDA ratio is -0.37, with an EV/FCF ratio of -0.51.
EV to Sales234.35
EV to EBITDA-0.37
EV to Free Cash Flow-0.51
EV to Operating Cash Flow-0.51
Balance Sheet
Sonnet BioTherapeutics Holdings has $4.86M in cash and marketable securities with $110.96K in debt, giving a net cash position of -$4.75M billion.
Cash & Marketable Securities$4.86M
Total Debt$110.96K
Net Cash-$4.75M
Net Cash Per Share-$1.55
Tangible Book Value Per Share-$0.74
Margins
Gross margin is 100.00%, with operating margin of -63617.91%, and net profit margin of -39929.30%.
Gross Margin100.00%
Operating Margin-63617.91%
Pretax Margin-39929.30%
Net Profit Margin-39929.30%
EBITDA Margin-63617.91%
EBIT Margin-63617.91%
Analyst Forecast
The average price target for Sonnet BioTherapeutics Holdings is , which is 11.43% higher than the current price. The consensus rating is
Price Target
Price Target Upside
Analyst Consensus
Analyst Count0
Revenue Growth Forecast674.14%
EPS Growth Forecast89.05%